Why choose Organoid Technology?

Preserves patient-specific tumor antigens

Directly derived from patient tissue and never passaged in host animals

Offers patient-matched normal organoids

Test off-tumor toxicities of your ADCs in matched normal organoids

Physiologically
relevant

Recapitulates the structure, function, and cellular profiles of patient tumor

True to patients’
response

Reflects variability observed in patient response, despite similar antigen expression

THE CHALLENGE

The Current ADC drug development needs a paradigm shift

Antibody-drug conjugates (ADCs) have achieved significant milestones, with 15 FDA approvals since 2000, due to their targeted mechanism of action. However, the drug development process remains highly complex, largely due to intricate pharmacodynamics and the limitations of current experimental systems. For instance, cell lines often overexpress target antigens, which can result in efficacy assessments that do not accurately reflect clinical conditions. Although patient-derived xenograft (PDX) models offer a more accurate representation of human tumors, they are expensive and may not capture the full spectrum of tumor variations. Furthermore, animal models often fall short in mimicking the complexity of human tumor biology and immune responses, with species differences further complicating the translation of preclinical findings to clinical outcomes.

Bring patient insights into your ADC preclinical drug development

Validate your ADC data in a patient-derived system

Partner with the pioneers in organoid technology

Target hypothesis validation

Organo-Flow

Precise TAA expression analysis in patient-derived organoids

Our cutting-edge flow cytometry platform provides unparalleled accuracy in assessing both internal and external target antigen (TAA) expression in patient-derived organoids. Our comprehensive analysis empowers you to:

  • Validate differential TAA expression: Accurately identify variations in target expression between diseased and normal tissue.
  • Assess TAA expression across indications: Evaluate the presence and abundance of your target antigen across a panel of organoids across different oncological indications

book your screen

ideal for lead or indication selection

ADC Efficacy & Safety Screen

Test the efficacy & safety of your ADC candidates across various tumor types and oncological indications. We offer two sub-packages:

  • Efficacy Screen:  Pick a basket of tumor organoids across epithelial oncological indications and test the efficacy of your ADC
  • Efficacy & Safety Screen: Assesses both efficacy and off-target toxicity of your ADC in tumor and matched normal organoids

book your screen

Discover the science

POSTER PRESENTATION

Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity

download now

 

WHITEPAPER

Accelerating oncology drug discovery with HUB Organoids

download now

 

HUB Organoids® and Yamaha Motor announce their collaboration combining their proprietary technologies

BLOG

Forecasting a champion: How HUB Organoids® can speed up the drug development timeline to about five years

read more

 

X

Have any questions?

contact us